Quantcast

Latest Élan Stories

2011-05-09 08:00:00

CARLSBAD, Calif., May 9, 2011 /PRNewswire/ -- America's favorite cake maker, Buddy Valastro of Carlo's Bakery, can control and automate every aspect of his new 7,000 square foot New Jersey dream home, right from his iPhone or iPad with the ELAN g! Home Control System he just installed. (Photo: http://photos.prnewswire.com/prnh/20110509/NY97465 ) When Valastro moved in 2010, he didn't know much about home automation. He had a new music distribution system installed, but that was it. Two...

2010-09-02 06:50:00

PALM SPRINGS, Calif., Sept. 2 /PRNewswire/ -- Scientists at Elan Vital Pharmaceuticals announce anti-aging technology applications to a new product, De-Nouveau. De-Nouveau utilizes the Nobel Prize-winning discovery of the enzyme telomerase to change the anti-aging product market. Telomerase allows cellular DNA to recombine the same way a young person's DNA does. De-Nouveau by Elan Vital re-introduces the telomerase enzyme into the body to dramatically slow down the signs of aging....

2010-04-16 14:06:55

Data also showed reduced fatigue and improved cognition Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced results from a one-year, longitudinal health outcomes study (n=324) in which patients with multiple sclerosis (MS) who received 12 infusions of TYSABRI (natalizumab) reported improvements in quality of life (QoL) measures, as well as reduced fatigue and overall improved cognitive function, as measured by validated tools. The goal of the study, which was...

2010-03-17 07:30:00

SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain. Hydrocodone is the most widely prescribed drug in the United States, but...

2010-03-11 09:19:00

DUBLIN, March 11, 2010 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) (NYSE: ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). PRIALT is indicated in the United States for the management of severe chronic pain in patients for whom intrathecal ("IT") therapy is warranted, and who are intolerant of or refractory to other...

2010-02-23 05:00:00

LA JOLLA, Calif., Feb. 23 /PRNewswire/ -- Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company's board of directors. Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and Biogen Idec, where he served as Chief Operating Officer until his retirement in 2005. He...

2009-11-30 13:00:00

NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced $1.5 million in total awards to six research teams working to develop potentially disease-modifying therapies for Parkinson's disease. The funding was awarded under the Novel Approaches to Drug Discovery for Parkinson's Disease program, made possible by funding from Elan Corporation, plc (NYSE: ELN), a neuroscience-based biotechnology company. The Novel Approaches...

2009-09-24 10:04:00

NEW YORK, Sept. 24 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue. Drug Delivery Markets: Oral Delivery http://www.reportlinker.com/p0132601/Drug-Delivery-Markets-Oral-Delivery.html Since our last edition of this report in 2007, The oral drug delivery market is the largest segment of the drug delivery market, and there's no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend...